Early detection and innovative biologic treatment can prevent hospitalizations, improve quality of life, and extend the ...
Nearly 8% of Ohioans live with chronic obstructive pulmonary disease (COPD), a long-term, progressive lung disease that causes difficulty breathing. In fact, Ohio is among the states in the country ...
Regeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)), Sanofi ((SNYNF)), Sanofi ((DE:SNW)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock ...
To keep up with COPD research and care developments, the 2026 Global Initiative for Chronic Obstructive Lung Disease report ...
Join Rich Jones and Dr Mitchell Rothstein as they talk advances in COPD treatment. FREE lunch from Carrabba’s Italian Grill ...
What Is Jascayd, and Why Does It Matter? Jascayd (nerandomilast) is a new oral medicine approved to treat idiopathic pulmonary fibrosis (IPF) in adults. IPF is a rare and serious condition that causes ...
A retrospective cohort study of claims data demonstrated that following hospital discharge, patients adherent to YUPELRI experienced significantly fewer, and less severe, exacerbations and had ...
The FDA has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis, a rare, progressive lung disease that can cause scarring and breathing difficulties. The approval marks the ...
Research Triangle Park, NC and Silver Spring, MD United Therapeutics Corporation announced the FDA has issued an approvable letter for treprostinil sodium injection (Remodulin®) for the treatment of ...
Temple Health leads research showing how women and non-smokers face rising risks, and how new treatments are changing the future of care ...
A new discovery from the lab of YouYang Zhao, Ph.D., from Stanley Manne Children's Research Institute at Ann & Robert H.
Living Well with COPD provides free one-on-one COPD support, education and resources tailored for every stage of the disease. The program is created for all West Virginians affected by COPD, and their ...